Can Selective Beta-Blockers Be Prescribed Safely for Hemodialysis Patients? A Retrospective Review

Hospital Pharmacy

Volumn 39, Issue 2, 2004, Pages 144-148

  Faulkner, Michele ^a   Mears, A J ^b   Adams, Pat M ^b   Frock, James T ^b   Dunlay, Robert W ^b  

^a CREIGHTON UNIVERSITY SCHOOL OF PHARMACY AND HEALTH PROFESSIONS   (United States)

^b CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Beta blockers; End stage renal disease; Hemodialysis

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; NADOLOL; POTASSIUM;

ADULT; AGE; AGED; BETA ADRENERGIC RECEPTOR BLOCKING; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIALYSATE; DRUG SAFETY; FEMALE; HEMODIALYSIS; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; REVIEW;

EID: 1042291169     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: 10.1177/001857870403900209     Document Type: Review

References (34)

1. United States Renal Data Survey 1999 Annual Data Report. Causes of death in ESRD. Am J Kidney Dis. 1999;34(suppl 1):S87-94.
2. Burke SW, Solomon AJ. Cardiac complication of end-stage renal disease. Adv Ren Replace Ther. 2000;7(3):210-9.
3. Goldsmith DJA, Covic A. Coronary artery disease in patients with renal failure. Int J Clin Pract. 2001;55(3):196-210.
4. Akmal M. Hemodialysis in diabetic patients. Am J Kidney Dis. 2001;4(suppl 1):S195-9.
5. Al-Ahmad A, Sarnak MJ, Salem DN, et al. Cause and management of heart failure in patients with chronic renal disease. Semin Nephrol. 2001;21(1):3-12.
6. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). 2001. American College of Cardiology Web site. Available at: http://www.acc.org/clinical/guidelines/failure/hf_index.htm. Accessed on March 20, 2002.
7. Heart Failure Society of America. HFSA Guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction-pharmacological approaches. J Cardiac Fail. 1999;5:357-82.
8. Ryan TJ, Antman EM, Brooks NH, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: 1999 update: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Available at www.acc.org. Accessed on March 20, 2002.
9. Viskin S, Barron HV. Beta blockers prevent cardiac death following a myocardial infarction: So why are so many infarct survivors discharged without beta blockers? Am J Cardiol. 1996;78:821-2.
10. Barron HV, Viskin S, Lundstrom RJ, et al. β-blocker dosages and mortality after myocardial infarction. Arch Intern Med. 1998;158:449-53.
11. Frishman WH, Cheng A: Secondary prevention of myocardial infarction: Role of β-adrenergic blockers and angiotensin-converting enzyme inhibitors. Am Heart J. 1999;137:S25-34.
12. O'Rourke RA. Beta-adrenergic blocking agents or angiotensin-converting enzyme inhibitors, or both, for postinfarction patients with left ventricular dysfunction. J Am Coll Cardiol. 1997;29:237-9.
13. Beattie JN, Soman SS, Sandberg KR, et al. Determinants of mortality after myocardial infarction in patients with advanced renal dysfunction. Am J Kidney Dis. 2001;37(6):1191-200.
14. Schwartz AB, Cannon-Babb M. Hyperkalemia due to drugs in diabetic patients. Am Fam Physician. 1989;39(1):225-31.
15. Perazella MA. Drug-induced hyperkalemia: Old culprits and new offenders. Am J Med. 2000;109:307-14.
16. Ewart HS, Klip A. Hormonal regulation of the Na+-K+-ATPase: Mechanisms underlying rapid and sustained changes in pump activity. Am J Physiol. 1995;269:C295-311.
17. Uribarri J, Oh MS, Carroll HJ. Hyperkalemia in diabetes mellitus. J Diabet Complications. 1990;4(1):3-7.
18. Williams ME. Endocrine crises: Hyperkalemia. Crit Care Clin. 1991;7(1):155-74.
19. Yang WC, Huang TP, Ho LT, et al. Beta-adrenergic-mediated extrarenal potassium disposal in patients with end-stage renal disease: Effect of propranolol. Miner Electrolyte Metab. 1986;12(3):186-93.
20. Arrizabalage P, Montoliu J, Vea AM, et al. Increase in serum potassium caused by beta-2 adrenergic blockade in terminal renal failure: Absence of mediation by insulin or aldosterone. Proc Eur Dial Transplant Assoc. 1983;20:572-6.
21. Castellino P, Bia M, DeFronzo RA. Adrenergic modulation of potassium metabolism in uremia. Kidney Int. 1990;37:793-8.
22. Levinsky NG. Hyperkalemia. N Engl J Med. 1966;274:1076-7.
23. Wilcox RG. Randomized study of six beta-blockers and a thiazide diuretic in essential hypertension. BMJ. 1978;2:283-5.
24. MERIT-HF Investigators: Effect of metoprolol CRXL in congestive heart failure: Metoprolol CRXL randomized intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001-7.
25. CIBIS-II Investigators and Committees: The cardiac insufficiency bisoprolol study II (CIBIS-II): A randomized trial. Lancet 1999;353:9-13.
26. Venkatesan J, Henrich WL. Cardiac disease in chronic uremia: Management. Adv Ren Replace Ther. 1997;4(3):249-66.
27. Ridao N, Luño J, Garcia de Vinuesa S, et al. Prevalence of hypertension in renal disease. Nephrol Dial Transplant. 2001;16(suppl 11:70-3.
28. Mittal SK, Kowalski E, Trenkle J, et al. Prevalence of hypertension in a hemodialysis population. Clin Nephrol. 1999;51/21:77-82.
29. The Sixth Report of the Joint National Committee of Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157:2413-46.
30. Ponce SP, Jennings AE, Madias NE, et al. Drug-induced hyperkalemia. Medicine. 1985;64(6):357-70.
31. Allon M. Hyperkalemia in end-stage renal disease: Mechanisms and management. J Am Soc Nephrol. 1995;6:1134-42.
32. Wilkinson R. β-blockers and renal function. Drugs. 1982;23:195-206.
33. United States Renal Data Survey 1999 Annual Data Report. Patient characteristics at the start of ESRD: Data from the HCFA medical evidence form. Am J Kidney Dis. 1999;34(suppl 1):S63-73.
34. Herlitz J, Malmberg K. How to improve the cardiac prognosis for diabetes. Diabetes Care. 1999;22(suppl 21:B89-96.